NCT07028073View on ClinicalTrials.gov

A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

May 15, 2027

Study Completion Date

December 31, 2027

Conditions
Acute Myeloid Leukemia With T(8;21)(Q22;Q22)Acute Myeloid Leukemia With T(16;16)(P13;Q22)KIT Gene MutationAvapritinib
Interventions
DRUG

Group A (FIT): Avapritinib + IA regimen

Cytarabine 100mg/m² days 1-7 Idarubicin 12mg/m² days 1-3 Avapritinib orally on days 8-21 (28-day cycle)

DRUG

Group B (UNFIT): Avapritinib + VA regimen

Venetoclax 100mg day 1, 200mg day 2, 400mg days 3-28 Azacitidine 75mg/m² days 1-7 Avapritinib orally on days 8-21 (28-day cycle)

Trial Locations (1)

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER